Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment

被引：0
|
作者：
Philip J. Mease
Alice B. Gottlieb
Alexis Ogdie
Iain B. McInnes
Soumya D. Chakravarty
Emmanouil Rampakakis
Alexa Kollmeier
Xie L. Xu
May Shawi
Frederic Lavie
Mitsumasa Kishimoto
Proton Rahman
机构：
[1] Swedish Medical Center/Providence St. Joseph Health and University of Washington,Department of Dermatology
[2] Icahn School of Medicine at Mount Sinai,Division of Rheumatology
[3] University of Pennsylvania School of Medicine,College of Medical Veterinary and Life Sciences
[4] University of Glasgow,Department of Pediatrics
[5] Janssen Scientific Affairs,Immunology
[6] LLC,Immunology
[7] Drexel University College of Medicine,Department of Nephrology and Rheumatology
[8] McGill University,Discipline of Medicine, Division of Rheumatology
[9] JSS Medical Research,undefined
[10] Janssen Research & Development,undefined
[11] LLC,undefined
[12] Janssen Research & Development,undefined
[13] LLC,undefined
[14] Janssen Cilag Global Medial Affairs,undefined
[15] Immunology Global Medical Affairs,undefined
[16] Kyorin University School of Medicine,undefined
[17] Memorial University of Newfoundland,undefined
来源：
Clinical Rheumatology | 2024年 / 43卷
关键词：
DAPSA; Guselkumab; Psoriatic arthritis; Radiographic progression; Structural joint damage; vdH-S score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：241 / 249
页数：8
相关论文
共 50 条
  • [1] Earlier clinical response predicts low rates of radiographic progression in biologic-naive patients with active psoriatic arthritis receiving guselkumab treatment
    Mease, Philip J.
    Gottlieb, Alice B.
    Ogdie, Alexis
    McInnes, Iain B.
    Chakravarty, Soumya D.
    Rampakakis, Emmanouil
    Kollmeier, Alexa
    Xu, Xie L.
    Shawi, May
    Lavie, Frederic
    Kishimoto, Mitsumasa
    Rahman, Proton
    CLINICAL RHEUMATOLOGY, 2024, 43 (01) : 241 - 249
  • [2] EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
    Mease, P. J.
    Gottlieb, A. B.
    Ogdie, A.
    Mcinnes, I.
    Chakravarty, S. D.
    Rampakakis, E.
    Kollmeier, A.
    Xu, X. L.
    Shawi, M.
    Lavie, F.
    Kishimoto, M.
    Rahman, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 828 - 829
  • [3] Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and-2 Randomized Clinical Trials
    Mease, Philip
    Korotaeva, Tatiana
    Shesternya, Pavel
    Kokhan, Muza
    Rukavitsyn, Anton
    Vasilchenkov, Dmitry
    Sharaf, Mohamed
    Lavie, Frederic
    Deodhar, Atul
    RHEUMATOLOGY AND THERAPY, 2024, 11 (06) : 1551 - 1567
  • [4] Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis
    Michael Schiff
    Louis Bessette
    Clinical Rheumatology, 2010, 29 : 583 - 591
  • [5] Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis
    K. Ebina
    M. Hirao
    J. Hashimoto
    H. Matsuoka
    T. Iwahashi
    R. Chijimatsu
    Y. Etani
    G. Okamura
    A. Miyama
    H. Yoshikawa
    Osteoporosis International, 2018, 29 : 1627 - 1636
  • [6] Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-na⟨ve rheumatoid arthritis
    Ebina, K.
    Hirao, M.
    Hashimoto, J.
    Matsuoka, H.
    Iwahashi, T.
    Chijimatsu, R.
    Etani, Y.
    Okamura, G.
    Miyama, A.
    Yoshikawa, H.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (07) : 1627 - 1636
  • [7] Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice
    Gratacos-Masmitja, Jordi
    Catalan, Emma Beltran
    Vega, Jose Luis alvarez
    Urruticoechea-Arana, Ana
    Fito, Concepcion
    Maceiras, Francisco
    Otano, Joaquin Maria Belzunegui
    Melon, Julia Fernandez
    Carmona, Eugenio Chamizo
    Hernandez, Miguel angel Abad
    Vilamajo, Inmaculada Ros
    Oreiro, Sonia Castro
    Alfonso, Eva Pascual
    Alonso, Juan Carlos Torre
    REUMATOLOGIA CLINICA, 2024, 20 (01): : 24 - 31
  • [8] The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Steven Peterson
    Prasheen Agarwal
    Feifei Yang
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Natalie J. Shiff
    Bei Zhou
    Chenglong Han
    May Shawi
    William Tillett
    Philip J. Mease
    Advances in Therapy, 2022, 39 : 4613 - 4631
  • [9] Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
    Dafna D. Gladman
    Philip J. Mease
    Paul Bird
    Enrique R. Soriano
    Soumya D. Chakravarty
    May Shawi
    Stephen Xu
    Sean T. Quinn
    Cinty Gong
    Evan Leibowitz
    Denis Poddubnyy
    Lai-Shan Tam
    Philip S. Helliwell
    Arthur Kavanaugh
    Atul Deodhar
    Mikkel Østergaard
    Xenofon Baraliakos
    Trials, 23
  • [10] EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
    Tillett, W.
    Coates, L.
    Vis, M.
    Soriano, E.
    Merola, J. F.
    Zimmermann, M.
    Shawi, M.
    Sharaf, M.
    Nash, P.
    Helliwell, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1131 - 1132
12345